CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 12, 2006--CombinatoRx, Incorporated (NASDAQ: CRXX - News) today announced the presentation of preclinical data on CRx-401, a novel insulin sensitizer with anti-diabetic activity, at the 66th Scientific Sessions of the American Diabetes Association, June 9-13, 2006 in Washington, D.C. The data demonstrate that CRx-401, a novel combination drug candidate in preclinical development for diabetes, acts synergistically to increase glucose uptake in vitro in insulin-sensitive cell types. The anti-diabetic activity of CRx-401 translates in vivo in a rat model of insulin resistance, significantly reducing fasting blood glucose and homeostasis model assessment-insulin resistance (HOMA-IR) scores, while the single agents do not improve these measures. CRx-401 also reduced body weight gain as compared both to thiazolidinedione-treated and to placebo-treated animals. Thiazolidinedione (TZD) is a class of drugs for the treatment of type 2 diabetes.
